Phosphodiesterase: Difference between revisions
imported>Robert Badgett No edit summary |
imported>Robert Badgett |
||
| Line 12: | Line 12: | ||
===Cyclic Nucleotide Phosphodiesterases, Type 3 (PDE-3)=== | ===Cyclic Nucleotide Phosphodiesterases, Type 3 (PDE-3)=== | ||
Inamrinone (previously named amrinone) and milrinone are inhibitors of PDE-3 and have been studied for use in the treatment of [[heart failure]]. These drugs improve cardiac contractility as well as increase vasodilation. Milrinone has significant adverse effects in [[randomized controlled trial]]s.<ref name="pmid2646536">{{cite journal |author=DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R |title=A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure |journal=N. Engl. J. Med. |volume=320 |issue=11 |pages=677–83 |year=1989 |month=March |pmid=2646536 |doi= |url= |issn=}}</ref><ref name="pmid1944425">{{cite journal |author=Packer M, Carver JR, Rodeheffer RJ, ''et al'' |title=Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group |journal=N. Engl. J. Med. |volume=325 |issue=21 |pages=1468–75 |year=1991 |month=November |pmid=1944425 |doi= |url= |issn=}}</ref> | |||
===Cyclic Nucleotide Phosphodiesterases, Type 4 (PDE-4)=== | ===Cyclic Nucleotide Phosphodiesterases, Type 4 (PDE-4)=== | ||
Revision as of 20:28, 15 July 2008
In biochemistry, a phosphodiesterases are a "class of enzymes that catalyze the hydrolysis of one of the two ester bonds in a phosphodiester compound."[1]
An important function of phosphodiesterases is terminating signal transduction by the breakdown of the second messengers cyclic AMP and cyclic GMP by hydrolysis.
Classification
Cyclic Nucleotide Phosphodiesterases, Type 1 (PDE-1)
These phosphodiesterases have additional specificity for cyclic GMP.
Cyclic Nucleotide Phosphodiesterases, Type 2 (PDE-2)
These phosphodiesterases have additional specificity for cyclic GMP.
Cyclic Nucleotide Phosphodiesterases, Type 3 (PDE-3)
Inamrinone (previously named amrinone) and milrinone are inhibitors of PDE-3 and have been studied for use in the treatment of heart failure. These drugs improve cardiac contractility as well as increase vasodilation. Milrinone has significant adverse effects in randomized controlled trials.[2][3]
Cyclic Nucleotide Phosphodiesterases, Type 4 (PDE-4)
Cyclic Nucleotide Phosphodiesterases, Type 5 (PDE-5)
Sildenafil, vardenafil, and tadalafil are phosphodiesterase inhibitors of PDE-5 which increase cyclic GMP levels leading to smooth muscle relaxation. These are used to treat erectile dysfunction and as well as pulmonary hypertension.
These phosphodiesterases have additional specificity for cyclic GMP.
Cyclic Nucleotide Phosphodiesterases, Type 6 (PDE-6)
These phosphodiesterases have additional specificity for cyclic GMP.
Cyclic Nucleotide Phosphodiesterases, Type 7 (PDE-7)
References
- ↑ Anonymous (2024), Phosphodiesterase (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R (March 1989). "A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure". N. Engl. J. Med. 320 (11): 677–83. PMID 2646536. [e]
- ↑ Packer M, Carver JR, Rodeheffer RJ, et al (November 1991). "Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group". N. Engl. J. Med. 325 (21): 1468–75. PMID 1944425. [e]